Recombinant anti mouse cd40 ligand

Phycoerythrin-conjugated anti-mouse CD80 and CD86; CD137 ligand; CD40, CD70, ICOS ligand and OX40 antibodies; phycoerythrin-CY7–conjugated anti-mouse CD8 antibody; and isotype control antibodies were purchased from BioLegend (San Diego, CA). Anti-mouse phospho-NF-κB p65 (Ser536), NF-κB p65, phospho-IkBα (Ser32), IkBα (Ser32), phospho-Ikkα/β (Ser176/180), Ikkα, PCAF, and β-actin antibodies were purchased from Cell Signaling Technologies (Danvers, MA). The anti-mouse Rae-1 antibody was developed by the Monoclonal Antibody Core Facility at MD Anderson Cancer Center and validated in our previous study^{47 (link)}. Goat anti-mouse Alexa Fluor 405 antibodies were purchased from Life Technologies. Horseradish peroxidase–conjugated anti-mouse immunoglobulin G (IgG) and anti-rabbit IgG were purchased from Cell Signaling Technologies. Anti-mouse CD137 and CD40 ligand-blocking antibodies were purchased from R&D Systems. A recombinant anti-mouse CD137 antibody was purchased from BioLegend, and a recombinant anti-mouse CD40 ligand was purchased from eBioscience (San Diego, CA). Anti-mouse IFNγ- and TNFα-neutralizing antibodies were purchased from R&D Systems.